Robert Pordy

16.7k total citations · 8 hit papers
107 papers, 6.6k citations indexed

About

Robert Pordy is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Economics and Econometrics. According to data from OpenAlex, Robert Pordy has authored 107 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Surgery, 53 papers in Cardiology and Cardiovascular Medicine and 40 papers in Economics and Econometrics. Recurrent topics in Robert Pordy's work include Lipoproteins and Cardiovascular Health (82 papers), Health Systems, Economic Evaluations, Quality of Life (30 papers) and Lipid metabolism and disorders (29 papers). Robert Pordy is often cited by papers focused on Lipoproteins and Cardiovascular Health (82 papers), Health Systems, Economic Evaluations, Quality of Life (30 papers) and Lipid metabolism and disorders (29 papers). Robert Pordy collaborates with scholars based in United States, France and Canada. Robert Pordy's co-authors include Christelle Lorenzato, Umesh Chaudhari, Jennifer G. Robinson, John J.P. Kastelein, Jean Bergeron, Frederick J. Raal, Erik S.G. Stroes, Michel Farnier, Daniel Gaudet and Michel Krempf and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Robert Pordy

102 papers receiving 6.5k citations

Hit Papers

Efficacy and Safety of Al... 2012 2026 2016 2021 2015 2020 2012 2015 2015 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
    2015 1.7k citations Erik S.G. Stroes, Frederick J. Raal et al. New England Journal of Medicine profile →
  2. Evinacumab for Homozygous Familial Hypercholesterolemia
    2020 470 citations Frederick J. Raal, Robert S. Rosenson et al. New England Journal of Medicine profile →
  3. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
    2012 463 citations Daniel Gaudet, Robert Pordy et al. profile →
  4. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
    2015 418 citations John J.P. Kastelein, G. Kees Hovingh et al. European Heart Journal profile →
  5. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
    2015 345 citations Robert Pordy, Daniel A. Gipe et al. Journal of clinical lipidology profile →
  6. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
    2015 316 citations Robert Pordy et al. European Heart Journal profile →
  7. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
    2015 291 citations Robert Pordy et al. profile →
  8. Evinacumab in Patients with Refractory Hypercholesterolemia
    2020 215 citations Robert S. Rosenson, Seth J. Baum et al. New England Journal of Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Robert Pordy 5.5k 2.2k 1.8k 1.6k 1.0k 107 6.6k
Gisle Langslet 4.3k 0.8× 1.6k 0.7× 869 0.5× 1.4k 0.9× 707 0.7× 73 5.1k
David Kallend 5.4k 1.0× 1.2k 0.5× 1.8k 1.0× 2.6k 1.6× 1.5k 1.4× 99 7.8k
R Češka 3.4k 0.6× 1000 0.5× 1.1k 0.6× 1.3k 0.8× 742 0.7× 174 4.8k
Edwin J. Whitney 4.1k 0.7× 1.3k 0.6× 1.2k 0.7× 2.1k 1.3× 958 0.9× 25 5.1k
Alexandra Langendörfer 4.1k 0.7× 1.4k 0.6× 1.2k 0.6× 2.0k 1.3× 955 0.9× 15 5.1k
S. Féasson 3.7k 0.7× 1.2k 0.6× 1.6k 0.9× 1.5k 1.0× 631 0.6× 6 5.4k
William B. Kruyer 3.4k 0.6× 1.2k 0.6× 1.2k 0.6× 1.5k 1.0× 752 0.7× 17 4.4k
Narimon Honarpour 2.7k 0.5× 931 0.4× 780 0.4× 840 0.5× 518 0.5× 51 3.8k
Tim Crowe 5.6k 1.0× 633 0.3× 2.1k 1.2× 1.9k 1.2× 994 1.0× 38 7.3k
James H. Revkin 3.2k 0.6× 485 0.2× 1.2k 0.7× 2.3k 1.5× 879 0.8× 39 4.8k

Countries citing papers authored by Robert Pordy

Since Specialization
Citations

This map shows the geographic impact of Robert Pordy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Pordy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Pordy more than expected).

Fields of papers citing papers by Robert Pordy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Pordy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Pordy. The network helps show where Robert Pordy may publish in the future.

Co-authorship network of co-authors of Robert Pordy

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Pordy. A scholar is included among the top collaborators of Robert Pordy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Pordy. Robert Pordy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Banerjee, Poulabi, et al.. (2025). Treatment With Evinacumab Links a New Pathogenic Variant in the LPL Gene to Persistent Chylomicronemia. Journal of the Endocrine Society. 9(4). bvaf025–bvaf025. 2 indexed citations
2.
Brinton, Eliot A., Frederick J. Raal, Jean Bergeron, et al.. (2025). Evinacumab in patients aged 5–17 years with homozygous familial hypercholesterolemia. Atherosclerosis. 413. 120627–120627.
3.
Rosenson, Robert S., Richard T. De George, Robert J. Sanchez, et al.. (2025). Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial. Journal of clinical lipidology. 19(5). 1223–1233. 1 indexed citations
4.
Dingman, Robert, Jeanne Mendell, Katy C. Norman, et al.. (2025). Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia. CPT Pharmacometrics & Systems Pharmacology. 14(11). 1835–1847. 1 indexed citations
5.
Wiegman, Albert & Robert Pordy. (2025). Evinacumab for children with homozygous familial hypercholesterolemia: a plain language summary. Future Cardiology. 21(3). 139–147.
6.
Trotter, Dinko González, Prodromos Parasoglou, Anita Boyapati, et al.. (2024). 34-OR: The Effect of Combined Activin A and Myostatin Blockade on Body Composition—A Phase 1 Trial. Diabetes. 73(Supplement_1). 2 indexed citations
7.
Bittner, Vera, Gregory G. Schwartz, Deepak L. Bhatt, et al.. (2024). Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study. Journal of clinical lipidology. 18(4). e548–e561. 9 indexed citations
8.
Wiegman, Albert, Susanne Greber‐Platzer, Shazia Ali, et al.. (2023). Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia. Circulation. 149(5). 343–353. 41 indexed citations
9.
Pordy, Robert, et al.. (2023). CLINICAL TRIAL WITH THE ANGPTL3 MONOCLONAL ANTIBODY EVINACUMAB IDENTIFIES A NEW RARE CHYLOMICRONEMIA CAUSING VARIANT IN THE LPL GENE. Canadian Journal of Cardiology. 39(10). S183–S183. 1 indexed citations
10.
Mohammadi, Kusha, Gregory G. Schwartz, Philippe Gabríel Steg, et al.. (2023). Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Medicine. 12(16). 16859–16868. 3 indexed citations
11.
Raal, Frederick J., Robert S. Rosenson, Laurens F. Reeskamp, et al.. (2023). The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. JACC Advances. 2(9). 100648–100648. 15 indexed citations
12.
Szarek, Michael, Marco Valgimigli, Md. Shahidul Islam, et al.. (2023). Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome. Canadian Journal of Cardiology. 39(10). 1315–1324. 3 indexed citations
13.
Moriarty, Patrick M., Philippe Gabríel Steg, Jennifer McGinniss, et al.. (2022). Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. Journal of clinical lipidology. 16(5). 747–756. 2 indexed citations
14.
White, Harvey D., Gregory G. Schwartz, Michael Szarek, et al.. (2021). Alirocumab after acute coronary syndrome in patients with a history of heart failure. European Heart Journal. 43(16). 1554–1565. 24 indexed citations
15.
Schwartz, Gregory G., Philippe Gabríel Steg, Deepak L. Bhatt, et al.. (2021). Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol. Circulation. 143(11). 1109–1122. 56 indexed citations
16.
Raal, Frederick J., Robert S. Rosenson, Laurens F. Reeskamp, et al.. (2020). Evinacumab for Homozygous Familial Hypercholesterolemia. New England Journal of Medicine. 383(8). 711–720. 470 indexed citations breakdown →
17.
18.
Banerjee, Poulabi, Kuo‐Chen Chan, Asier Benito‐Vicente, et al.. (2019). Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arteriosclerosis Thrombosis and Vascular Biology. 39(11). 2248–2260. 64 indexed citations
19.
Sinnaeve, Peter, Gregory G. Schwartz, Daniel Wojdyla, et al.. (2019). Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal. 41(24). 2248–2258. 59 indexed citations
20.
Dunbar, Richard L., Daniel A. Gipe, Robert Pordy, et al.. (2016). Abstract 19133: Inhibition of ANGPTL3 by Evinacumab Reduced Triglycerides (TGs) and LDL-C in Subjects Presenting With Modest Elevations in TGs and/or LDL-C, Recapitulating the Hypolipidemic Effects of Loss-of-Function (LoF) Mutations of ANGPTL3. Circulation. 134. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gisle Langslet Breakdown of academic impact, for papers by David Kallend Breakdown of academic impact, for papers by R Češka Breakdown of academic impact, for papers by Edwin J. Whitney Breakdown of academic impact, for papers by Alexandra Langendörfer Breakdown of academic impact, for papers by S. Féasson Breakdown of academic impact, for papers by William B. Kruyer Breakdown of academic impact, for papers by Narimon Honarpour Breakdown of academic impact, for papers by Tim Crowe Breakdown of academic impact, for papers by James H. Revkin
Rankless by CCL
2026